March 23, 2022Open Access

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among adults with DKD, SGLT2i were associated with reduced risks of MACE, kidney outcomes, HHF, and death. With a few exceptions of more clear safety signals, we found overall limited data on the associations between SGLT2i and safety outcomes. More research is needed on the safety profile of SGLT2i in this population.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kazé et al. (Wed,) studied this question.

synapsesocial.com/papers/69e0ba5f46ce12fc61557569 https://doi.org/https://doi.org/10.1186/s12933-022-01476-x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes2020 · 1,214 citations
2Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,004 citations
3ESRD and Death after Heart Failure in CKD2014 · 46 citations
4Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?2020 · 43 citations
5Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program2019 · 129 citations

Me gusta

Guardar

Ver artículo completo